- Conditions
- Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-Naive B Cell Malignancies
- Interventions
- TL-895, Navtemadlin
- Drug
- Lead sponsor
- Telios Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Germantown, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,578
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 92
- States / cities
- Jasper, Alabama • Mobile, Alabama • Tucson, Arizona + 89 more
- Conditions
- Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
- Interventions
- Pristine™ Long-Term Hemodialysis Catheter
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 6
- States / cities
- Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
- Biological · Procedure · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching Placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- End Stage Renal Disease
- Interventions
- Expanded AD Choice, Expanded Life-sustaining Therapy Choice
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Camden, New Jersey • Philadelphia, Pennsylvania • Radnor, Pennsylvania + 1 more
- Conditions
- Hepatitis C
- Interventions
- SOF, VEL, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 40
- States / cities
- Long Beach, California • Los Angeles, California • Pasadena, California + 37 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- CNTX-4975-05, Placebo
- Drug
- Lead sponsor
- Centrexion Therapeutics
- Industry
- Eligibility
- 40 Years to 95 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Verekitug, Placebo
- Drug · Other
- Lead sponsor
- Upstream Bio Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 29
- States / cities
- Bakersfield, California • Encino, California • Lomita, California + 23 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
- Interventions
- Orca-T
- Biological
- Lead sponsor
- Orca Biosystems, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 21
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
- Interventions
- Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD
- Drug · Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Parkinson's Disease
- Interventions
- RM-131, Placebo
- Drug
- Lead sponsor
- Motus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Englewood, Colorado • Gainesville, Florida + 10 more
- Conditions
- Chronic Hepatitis, Hepatitis B
- Interventions
- Clevudine, Adefovir
- Drug
- Lead sponsor
- Pharmasset
- Industry
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Anaheim, California • Fresno, California + 36 more
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Interventions
- aleniglipron or placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Glendale, California • Montclair, California • Valparaiso, Indiana + 7 more
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- alemtuzumab, busulfan, cyclophosphamide, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia, B-Cell Lymphoma
- Interventions
- DTRMWXHS-12, DTRM-505, DTRM-555
- Drug
- Lead sponsor
- Zhejiang DTRM Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 3 more
- Conditions
- Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Graft-Versus-Host Disease
- Interventions
- Panobinostat (LBH589)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- PCI-32765
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New Hyde Park, New York • New York, New York + 3 more
- Conditions
- Cancer
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis C, Chronic
- Interventions
- BI 207127, BI 201335, Ribavirin, BI 207217
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 12
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Chronic Kidney Disease
- Interventions
- GCS-100
- Drug
- Lead sponsor
- La Jolla Pharmaceutical Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more
- Conditions
- Chronic Graft-versus-host Disease (cGVHD)
- Interventions
- Ruxolitinib, Prednisone
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Miami, Florida • Tampa, Florida • Kansas City, Kansas + 2 more
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, becatecarin, cisplatin
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 3
- States / cities
- San Antonio, Texas